诊断学理论与实践 ›› 2020, Vol. 19 ›› Issue (04): 334-338.doi: 10.16150/j.1671-2870.2020.04.002
叶蕾, 李浩榕
收稿日期:
2020-05-20
出版日期:
2020-08-25
发布日期:
2022-07-15
Received:
2020-05-20
Online:
2020-08-25
Published:
2022-07-15
中图分类号:
叶蕾, 李浩榕. 良恶性甲状腺结节的分子鉴别诊断进展[J]. 诊断学理论与实践, 2020, 19(04): 334-338.
[1] |
Burman KD, Wartofsky L. Clinical practice. Thyroid no-dules[J]. N Engl J Med, 2015, 373(24):2347-2356.
doi: 10.1056/NEJMcp1415786 URL |
[2] |
Haugen BR, Alexander EK, Bible KC, et al. 2015 Ame-rican Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer[J]. Thyroid, 2016, 26(1):1-133.
doi: 10.1089/thy.2015.0020 pmid: 26462967 |
[3] |
Hegedüs L. Clinical practice. The thyroid nodule[J]. N Engl J Med, 2004, 351(17):1764-1771.
doi: 10.1056/NEJMcp031436 URL |
[4] |
Mandel SJ. A 64-year-old woman with a thyroid nodule[J]. JAMA, 2004, 292(21):2632-2642.
pmid: 15572721 |
[5] |
Gharib H, Goellner JR. Fine-needle aspiration biopsy of the thyroid: an appraisal[J]. Ann Intern Med, 1993, 118(4):282-289.
pmid: 8420446 |
[6] |
Bongiovanni M, Spitale A, Faquin WC, et al. The Bethesda System for Reporting Thyroid Cytopathology: a meta-analysis[J]. Acta Cytol, 2012, 56(4):333-339.
doi: 10.1159/000339959 pmid: 22846422 |
[7] |
Xing M. Molecular pathogenesis and mechanisms of thyroid cancer[J]. Nat Rev Cancer, 2013, 13(3):184-199.
doi: 10.1038/nrc3431 URL |
[8] |
Cohen Y, Xing M, Mambo E, et al. BRAF mutation in papillary thyroid carcinoma[J]. J Natl Cancer Inst, 2003, 95(8):625-627.
doi: 10.1093/jnci/95.8.625 URL |
[9] |
Yoo SK, Lee S, Kim SJ, et al. Comprehensive analysis of the transcriptional and mutational landscape of follicular and papillary thyroid cancers[J]. PLoS Genet, 2016, 12(8):e1006239.
doi: 10.1371/journal.pgen.1006239 URL |
[10] |
Yoo SK, Song YS, Lee EK, et al. Integrative analysis of genomic and transcriptomic characteristics associated with progression of aggressive thyroid cancer[J]. Nat Commun, 2019, 10(1):2764.
doi: 10.1038/s41467-019-10680-5 URL |
[11] |
Calebiro D, Grassi ES, Eszlinger M, et al. Recurrent EZH1 mutations are a second hit in autonomous thyroid adenomas[J]. J Clin Invest, 2016, 126(9):3383-3388.
doi: 10.1172/JCI84894 pmid: 27500488 |
[12] |
Ye L, Zhou X, Huang F, et al. The genetic landscape of benign thyroid nodules revealed by whole exome and transcriptome sequencing[J]. Nat Commun, 2017, 8:15533.
doi: 10.1038/ncomms15533 URL |
[13] |
Goldner WS, Angell TE, McAdoo SL, et al. Molecular variants and their risks for malignancy in cytologically indeterminate thyroid nodules[J]. Thyroid, 2019, 29(11):1594-1605.
doi: 10.1089/thy.2019.0278 URL |
[14] |
Xing M, Alzahrani AS, Carson KA, et al. Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer[J]. JAMA, 2013, 309(14):1493-1501.
doi: 10.1001/jama.2013.3190 URL |
[15] |
Xing M, Liu R, Liu X, et al. BRAF V600E and TERT promoter mutations cooperatively identify the most aggressive papillary thyroid cancer with highest recurrence[J]. J Clin Oncol, 2014, 32(25):2718-2726.
doi: 10.1200/JCO.2014.55.5094 URL |
[16] |
Nikiforov YE, Ohori NP, Hodak SP, et al. Impact of mutational testing on the diagnosis and management of patients with cytologically indeterminate thyroid nodules: a prospective analysis of 1056 FNA samples[J]. J Clin Endocrinol Metab, 2011, 96(11):3390-3397.
doi: 10.1210/jc.2011-1469 pmid: 21880806 |
[17] | Nikiforova MN, Wald AI, Roy S, et al. Targeted next-generation sequencing panel (ThyroSeq) for detection of mutations in thyroid cancer[J]. J Clin Endocrinol Metab, 2013, 98(11):E1852-E1860. |
[18] |
Nikiforov YE, Carty SE, Chiosea SI, et al. Highly accurate diagnosis of cancer in thyroid nodules with follicular neoplasm/suspicious for a follicular neoplasm cytology by ThyroSeq v2 next-generation sequencing assay[J]. Cancer, 2014, 120(23):3627-3634.
doi: 10.1002/cncr.29038 pmid: 25209362 |
[19] |
Nikiforov YE, Carty SE, Chiosea SI, et al. Impact of the multi-gene ThyroSeq next-generation sequencing assay on cancer diagnosis in thyroid nodules with atypia of undetermined significance/follicular lesion of undetermined significance cytology[J]. Thyroid, 2015, 25(11):1217-1223.
doi: 10.1089/thy.2015.0305 pmid: 26356635 |
[20] |
Nikiforova MN, Mercurio S, Wald AI, et al. Analytical performance of the ThyroSeq v3 genomic classifier for cancer diagnosis in thyroid nodules[J]. Cancer, 2018, 124(8):1682-1690.
doi: 10.1002/cncr.31245 pmid: 29345728 |
[21] |
Steward DL, Carty SE, Sippel RS, et al. Performance of a multigene genomic classifier in thyroid nodules with indeterminate cytology: a prospective blinded multicenter study[J]. JAMA Oncol, 2019, 5(2):204-212.
doi: 10.1001/jamaoncol.2018.4616 pmid: 30419129 |
[22] | Chen T, Gilfix BM, Rivera J, et al. The role of the ThyroSeq v3 molecular test in the surgical management of thyroid nodules in the canadian public health care setting[J/OL]. Thyroid, 2020-05-05[2020-05-11]. https://pubmed.ncbi.nlm.nih.gov/32242511/. |
[23] |
Chudova D, Wilde JI, Wang ET, et al. Molecular classification of thyroid nodules using high-dimensionality genomic data[J]. J Clin Endocrinol Metab, 2010, 95(12):5296-5304.
doi: 10.1210/jc.2010-1087 pmid: 20826580 |
[24] |
Alexander EK, Kennedy GC, Baloch ZW, et al. Preope-rative diagnosis of benign thyroid nodules with indeterminate cytology[J]. N Engl J Med, 2012, 367(8):705-715.
doi: 10.1056/NEJMoa1203208 URL |
[25] |
Patel KN, Angell TE, Babiarz J, et al. Performance of a genomic sequencing classifier for the preoperative diagnosis of cytologically indeterminate thyroid nodules[J]. JAMA Surg, 2018, 153(9):817-824.
doi: 10.1001/jamasurg.2018.1153 URL |
[26] |
Livhits MJ, Kuo EJ, Leung AM, et al. Gene expression classifier vs targeted next-generation sequencing in the management of indeterminate thyroid nodules[J]. J Clin Endocrinol Metab, 2018, 103(6):2261-2268.
doi: 10.1210/jc.2017-02754 pmid: 29590358 |
[27] |
Nikiforova MN, Tseng GC, Steward D, et al. MicroRNA expression profiling of thyroid tumors: biological significance and diagnostic utility[J]. J Clin Endocrinol Metab, 2008, 93(5):1600-1608.
doi: 10.1210/jc.2007-2696 URL |
[28] |
Mazeh H, Deutch T, Karas A, et al. Next-generation sequencing identifies a highly accurate miRNA panel that distinguishes well-differentiated thyroid cancer from benign thyroid nodules[J]. Cancer Epidemiol Biomarkers Prev, 2018, 27(8):858-863.
doi: 10.1158/1055-9965.EPI-18-0055 URL |
[1] | 沈银忠. 《人类免疫缺陷病毒感染/艾滋病合并结核分枝杆菌感染诊治专家共识》解读[J]. 诊断学理论与实践, 2022, 21(04): 431-436. |
[2] | 何新, 陈慧, 冯炜炜. 机器学习算法在辅助超声诊断附件肿块良恶性中的应用研究进展[J]. 诊断学理论与实践, 2022, 21(04): 541-546. |
[3] | 赵然, 詹维伟, 侯怡卿. 计算机辅助诊断系统辅助超声诊断甲状腺弥漫性病变合并结节良恶性的应用价值[J]. 诊断学理论与实践, 2022, 21(03): 390-394. |
[4] | 刘畅, 曹华, 冯炜炜, 沈立翡. 皮肌炎合并妇科恶性肿瘤11例临床特征与短期随访结局分析[J]. 诊断学理论与实践, 2021, 20(01): 53-59. |
[5] | 周伟, 侯怡卿, 詹维伟. 超声造影及超声弹性成像在良恶性甲状腺结节鉴别诊断中的应用进展[J]. 诊断学理论与实践, 2020, 19(04): 344-349. |
[6] | 周建桥, 詹维伟. 2020年中国超声甲状腺影像报告和数据系统(C-TIRADS)指南解读[J]. 诊断学理论与实践, 2020, 19(04): 350-353. |
[7] | 郭艳, 葛娟娟, 陈晨, 尹吉明, 王小龙, 陈家庚, 杜燕伟, 段园园, 凡雪霖, 郑磊, 王西勇, 詹维伟, 张璐. 细针穿刺活检联合RJ-TIRADS在诊断老年甲状腺结节良恶性中的价值[J]. 诊断学理论与实践, 2020, 19(03): 286-291. |
[8] | 徐上妍, 贾晓红, 倪晓枫, 詹维伟. ACR-TIRADS与RJ-TIRADS描述词及分类在甲状腺结节评估者间的一致性研究[J]. 诊断学理论与实践, 2019, 18(2): 149-154. |
[9] | 杜云志, 冯菁华, 常春康. 二代测序技术在骨髓增生异常综合征临床诊断和治疗决策中的应用进展[J]. 诊断学理论与实践, 2019, 18(06): 685-671. |
[10] | 况李君, 王怡, 陆采葑, 樊金芳, 吴敏, 周伟. 甲状腺结节鳞状上皮化生1例报道及文献复习[J]. 诊断学理论与实践, 2019, 18(04): 423-427. |
[11] | 忻笑容, 吴云林, 陈平, 谢玲, 周郁芬, 俞骁珺, 罗方秀, 项明. 胃癌608例临床及病理特征分析[J]. 诊断学理论与实践, 2019, 18(04): 470-472. |
[12] | 季沁, 周一帆, 陈茉, 李杰, 丁文波, 钱涛, 褚晓秋, 王建华, 徐书杭, 刘超. 弹性成像联合ACR-TIRADS诊断甲状腺结节良恶性的临床价值研究[J]. 诊断学理论与实践, 2019, 18(03): 307-312. |
[13] | 冯国伟, 陈刚. 99mTc-MIBI SPECT/CT甲状旁腺显像发现颈部恶性肿瘤的价值及与超声对比[J]. 诊断学理论与实践, 2018, 17(06): 682-686. |
[14] | 李牛, 王剑. 精准医学时代遗传性疾病的分子诊断[J]. 诊断学理论与实践, 2018, 17(02): 136-140. |
[15] | 李芹芹, 叶廷军, 毛敏静. 甲状腺细针穿刺细胞学检查与甲状腺影像报告和数据系统分级对照分析[J]. 诊断学理论与实践, 2017, 16(06): 607-611. |
阅读次数 | ||||||
全文 |
|
|||||
摘要 |
|
|||||